Buy STIM by Nov 9, 2026.

Neuronetics reported Q2 revenue of $41.6M, up 9.1% YoY, with Greenbrook revenue up 16.8%. Adjusted EBITDA swung to a $0.3M profit from a $5.6M loss, while gross margin jumped to 51.1%. With 9.37M shares short, 33.19% short float, and 5.38 days to cover, STIM is up 20% with 4M shares traded, nearly 2x its 2.08M average volume. https://www.biospace.com/press-releases/neuronetics-reports-second-quarter-2026-financial-and-operating-results NFA DD